The first new drug of Globo h target! Taiwan Haoding antibody drug conjugate obi-999 launched the first human clinical research, treatment of a variety of solid tumors!

December 19, 2019 / bioun / -- Taiwan Haoding Biotechnology Co., Ltd (Obi Pharma, Inc., hereinafter referred to as Haoding) recently announced the launch of a phase I / II clinical study (nct04084366) to evaluate its antibody drug conjugate (ADC) obi-999 for the treatment of multiple solid tumors The study plans to recruit patients with solid tumors such as gastric cancer, pancreatic cancer, colorectal cancer and esophageal cancer, with the purpose of verifying the safety and preliminary efficacy of obi-999 in these patient groups The study is the first human clinical study to evaluate obi-999 Patients have been treated at MD Anderson Cancer Center of the University of Texas in the United States These patients have been diagnosed with cancer types that meet the research treatment plan, including pancreatic cancer and colorectal cancer These cancer areas have unmet medical needs At present, the treatment of obi-999 is still continuing, and no obvious safety problems or trends have been observed "We are very pleased to use obi-999 to treat the first batch of patients," said Dr apostolia tsimberidou, MD Anderson Cancer Center The abnormal expression of glycolipid globo-H in epithelial tumors makes it a very attractive target Obi-999 is expected to induce a clinically significant response " Obi-999 is a new, first in class antibody drug conjugate (ADC), which selectively targets glycolipid antigen Globo h, an antigen expressed in up to 15 epithelial cancers Obi-999 uses a proprietary connectivity technology that provides a consistent drug antibody ratio (DAR) for cancer drugs Obi-999 uses a kind of anti Globo h antibody to target the cancer cells with high expression of Globo h, releases small molecule chemotherapy drugs to the target cancer cells through the specificity of the antibody, and directly carries out cytotoxic treatment Globo h-targeted antibody obi-888 is currently in phase I / II clinical practice To evaluate its safety and efficacy as an immunooncology therapy In preclinical xenotransplantation animal models of various types of tumors (pancreas, lung, stomach and breast), obi-999 significantly reduced tumor volume at various doses In preclinical single dose and repeated dose toxicology studies, obi-999 showed good tolerance and safety Taiwan Haoding owns the global rights of obi-999 In addition to obi-999 and obi-888, there is a new generation of cancer vaccine obi-883 targeting Globo h in Haoding pipeline In addition, the company has developed vaccines, monoclonal antibodies and antibody drug conjugates for ssea-4 targets, and a prodrug for akr1c3 targets Origin of the original text: Obi Pharma announcements initiation of a phase 1 / 2 study of its anti drug drug converge (ADC) targeted cancer therapy, obi-999